NCT06329284Completed
Midkine Role With Deregulated Oxidative and Immune Milieu in Induction of Preeclampsia
Midkine Interplays With Oxidative Stress and Inflammatory Milieu to Induce Preeclampsia in Normotensive Pregnant Women
Source: ClinicalTrials.gov · Last updated 26 Mar 2024
Brief summary (registry, in English)
Preeclampsia (PE) is a hypertensive pregnancy-related disorder that endangers maternal and fetal outcomes and accounts for 9-10% of maternal mortalities with its early-onset phenotype is the most dangerous, but its etiology is still not fully elucidated. Midkine (MDK) is a multifunctional protein that plays a unique role in the development of hypertension (HTN), via its proatherogenic effect and induction of overexpression of angiotensin converting enzyme. Oxidative stress (OS) upregulates the expression of MDK and MDK induces propagation of neoangiogenesis and acts as chemotactic for neutrophils.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 80 (actual)
- First submitted
- 10 Mar 2024
- Start date
- 1 Jan 2023
- Primary completion date
- 15 Sept 2023
- Lead sponsor
- Benha University
- NCT number
- NCT06329284
What you commit to
- Study type: Interventional
- Participants enrolled: 80
- From 1 Jan 2023 to the primary completion date, 15 Sept 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Women with history of complicated pregnancy;
- Had manifest essential hypertension, Diabetes Mellitus or chronic kidney diseases;
- Had genetic disorders, coagulopathy, autoimmune diseases or maintained on immunosuppressive therapy.
Other
- Had multiple gestational sacs, morbid obesity with Body Mass Index at time of pregnancy diagnosis over 35 kg/m2;
Who the study is looking for
- Newly pregnant normotensive (NT) women with singleton fetus;
- Free of the Exclusion Criteria.
Age in the registry: 21 years to 50 years · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Banha University Coordinator of this site? Confirm its status | Banhā | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.